Trust Point Inc’s Vertex Pharmaceuticals VRTX Stock Holding History

Trust Point Inc’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$394K	Buy	793 +21	+3%	+$9.31K	0.03%	275
2026 Q1	$345K	Buy	772 +272	+54%	+$127K	0.03%	345
2025 Q4	$227K	Buy	+500	New	+$216K	0.02%	437
2025 Q2	–	Sell	-437	Closed	-$212K	–	468
2025 Q1	$212K	Sell	437 -738	-63%	-$344K	0.02%	431
2024 Q4	$473K	Buy	1,175 +59	+5%	+$27.3K	0.03%	301
2024 Q3	$519K	Buy	1,116 +37	+3%	+$17.8K	0.04%	271
2024 Q2	$506K	Buy	1,079 +22	+2%	+$9.55K	0.04%	263
2024 Q1	$442K	Buy	+1,057	New	+$447K	0.03%	314

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

GIA

Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return

IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Trust Point Inc's VRTX Position: Q2 2026 in Review

Trust Point Inc increased its Vertex Pharmaceuticals (VRTX) stake by 2.7% in Q2 2026, buying an estimated $9.31K and bringing the position to 793 shares worth $394K. The position accounts for 0.03% of the portfolio, ranked #275.

Trust Point Inc first reported a position in VRTX in Q1 2024 and has held it in 8 quarters since. The position peaked at $519K in Q3 2024. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Trust Point Inc held 793 shares of Vertex Pharmaceuticals worth $394K as of Q2 2026.
Trust Point Inc bought 21 Vertex Pharmaceuticals shares in Q2 2026, an estimated $9.31K.
Vertex Pharmaceuticals made up 0.03% of Trust Point Inc's portfolio in Q2 2026, its #275 holding.
Trust Point Inc first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 8 quarters since.
Trust Point Inc's Vertex Pharmaceuticals position peaked at $519K in Q3 2024.
334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Trust Point Inc's 13F filing for Q2 2026, filed 8 Jul 2026.